Sygnature Discovery, an integrated drug discovery contract research organization (CRO), has completed a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million ($1.3 million) investment. The expanded HTC platform is now capable of producing double its previous output within the same timeframe. This aims to provide Sygnature’s clients with quicker access to compounds, potentially accelerating drug discovery timelines and ...